Navigation Links
Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
Date:4/29/2009

he Dow AgroSciences team has done an outstanding job of exploiting the powerful science of our ZFP platform."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, human, plant and research applications of Sangamo's ZFP technology platform, strategic partnerships with collaborators and clinical tri
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
3. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
5. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
6. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
8. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
9. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Ontotext S4 , The Self Service ... Now the same enterprise hardened text mining, Linked ... data is available to start-ups and mid-size businesses at ... that do not have resources to evaluate and prototype ... since there is no need for on premise hardware ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... BEDFORD, Mass., Sept. 2 VisEn Medical Inc., a leader ... today the commercial launch of its new Annexin-Vivo 750 imaging ... . The new Annexin-Vivo 750 agent is based on ... It is expected to significantly expand research areas and enhance drug development ...
... , , SAN DIEGO, Sept. 2 ... OPTR ) lead developmental product candidates will be ... and Chemotherapy (ICAAC) to be held at The Moscone Center in San ... http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , , ...
... , SILVER SPRING, Md., Sept. 1 United Therapeutics ... of Directors has approved and declared a stock split. The ... dividend, in which one share of United Therapeutics common stock will ... (or held in treasury) at the close of business on the ...
Cached Biology Technology:VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 2VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 3Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend 2
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2
... Saturday 02 April 2011: Promising new viral hepatitis data ... entry inhibitors --a new mechanism of action for drugs ... new hepatitis B and hepatitis D treatments for many ... replication (e.g. nucleotide/side analogues), and can lead to the ...
... greenhouse industry is big business in the United ... agricultural sales. Most of the ornamental plants grown ... greenhouse operations. These operations are classified as "intensive ... expensive resources (labor, water, and fertilizers) to produce ...
... on England,s unused agricultural land could produce enough biomass ... industry or the environment, according to research led by ... The study, funded by the UK Energy Research Centre ... which looks at the potential of planting short rotation ...
Cached Biology News:Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infection 2Green industry knowledge center introduced 2Green industry knowledge center introduced 3Short rotation energy crops could help meet UK's renewable energy targets 2
... The Fujifilm Life Science FLA-7000 excels at ... CBB-stained gel documentation. It features four easy-to-access ... and a filter for Imaging Plates) for ... a customizable choice of four kinds of ...
... has been optimized for the analysis of ... software to quickly and accurately locate and ... an ELISA plate or each section of ... been customized to incorporate standard ELISA analysis ...
For microscopy...
... General description: Humidity wells in the ... maintain chamber humidity and probe hydration around ... seal eliminates the risk of waterbath contamination. ... constant temperature waterbaths or hybridisation ovens. Linkage: ...
Biology Products: